• 單元主視覺

New Drug Development

Sunnypharmtech New Drug Development
505(B)2 PROJECTS
Cancer Supportive Care: ASN-02
  • ASN-02 is a 505(b)(2) new drug for cancer supportive cares, its therapeutic categories include Oral Mucositis, Radiation-induced acute dermatitis, chronic fibrosis, G.I. distress, cancer-related fatigue.
  • More than 30 patents were granted worldwide covering cancer supportive care as well as other indications including anti-pruritus, skin disorders, joint destruction prevention, wound healing, etc.
  • Phase II Clinical Study for CCRT-induced Oral Mucositis was completed.
  • Flexible cooperative models will be adopted for commercialization.

研發進度如下所示:

ASN-02 SUPPORTIVE CANCER CARE
INDICATION FORMULATION DEVELOPMENT STAGE
CCRT1 CANCER THERAPY-INDUCED ORAL MUCOSITIS ASN-020 2.5% ORAL RINSE PHASE II
RADIATION-INDUCED ACUTE DERMATITIS ASN-022 2.5% TOPICAL GEL CLINICAL PROTOCOL FOR PHASE II
NON-CANCER RELATED
INDICATION FORMULATION DEVELOPMENT STAGE
PRURITUS WYN 2.5% TOPICAL GEL CLINICAL PROTOCOL FOR PHASE II
ROSACEA WYN 2.5% TOPICAL GEL CLINICAL PROTOCOL FOR PHASE II
Home/Product R&D /New Drug Development